Enanta Pharmaceuticals | ENTA - Koszty Sprzedaży I Administracji





Koszty Sprzedaży I Administracji Zmiana Data
AbbVie USD 3.58B 316M 2026-03
Amgen USD 1.58B 354M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 41.74M 4.28M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Biogen USD 554.3M 128.2M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Gilead Sciences USD 1.45B 326M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Immunic USD 3.45M 451K 2025-12
Incyte USD 328.1M 62.31M 2026-03
Insmed USD 247.26M 34.78M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
J&J USD 6.03B 719M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Ligand Pharmaceuticals USD 20.84M 4.19M 2026-03
Merck USD 2.67B 180M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.14B 296M 2026-03
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03